ArticleBMJ open2023

Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury.

Peter Pickkers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.